Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
Coronary procedures
Coronavirus
Coverage with evidence development (CED)
Critical care
See all tags

Dutch Healthcare Institute implemented the MedTech Horizon Scan

Dutch Healthcare Institute (ZIN) implemented the MedTech Horizon Scan to gain a better insight into the arrival of medical technological innovations (MedTech). The objective of the MedTech Horizon Scan is to map the rise of high-risk medical technology for ZIN and all parties in the field. It concerns medical technologies and digital applications that are expected to be seen in healthcare in the next 1-3 years.

The Dutch Healthcare Institute (ZIN) will also use this information for its agenda, such as the further development of basic health insurance package and the clarification of package issues.

One of the reports published by ZIN under MedTech Horizon Scan concerns diabetes care. 

See more information in Dutch here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.

Tags
Netherlands
Health technology assessment

The latest related news

25
Nov 2024

Dutch Healthcare Authority updates in the policy framework for small-scale experiments since 2025

In November 2024, the Dutch Healthcare Authority (NZa) published an updated regulation and policy framework for small-scale experiments to introduce innovations, which will enter into force on January 01, 2025. The small-scale experiments for introducing innovations apply to innovative medical procedures that improve the organization and provision of patient care (including online consultation, telemonitoring, home neuromodulation, school counseling, etc.) but do not have enough evidence to obtain coverage within basic health insurance.
Read more
14
Nov 2024

The "Subsidy scheme for promising care" will be discontinued in the Netherlands

In October 2024, the Ministry of Health, Welfare, and Sport decided to discontinue the "Subsidy scheme for promising care," which was implemented in 2019 to support the development of missing clinical and economic evidence for promising care that otherwise cannot be covered within basic health insurance. There are 28 ongoing projects, and some new projects will be awarded the subsidy in the 2025 round.
Read more